样式: 排序: IF: - GO 导出 标记为已读
-
Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-15 Gautham Gampa, Phillip Spinosa, Jennifer Getz, Yu Zhong, Wendy Halpern, Emel Esen, John Davies, Cassie Chou, Mandy Kwong, Yingyun Wang, Teresita L. Arenzana, Vittal Shivva, Mahrukh Huseni, Robert Hsieh, Jill Schartner, James T. Koerber, Sascha Rutz, Iraj Hosseini
-
Arrestin-centred interactions at the membrane and their conformational determinants Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-13 Owen Underwood, Raphael Silvanus Haider, Julie Sanchez, Meritxell Canals
More than 30 years after their discovery, arrestins are recognised multiprotein scaffolds that play essential roles in G protein-coupled receptor (GPCR) regulation and signalling. Originally named for their capacity to hinder GPCR coupling to G proteins and facilitate receptor desensitisation, arrestins have emerged as key hubs for a myriad of other functions, including receptor internalisation and
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-11
No abstract is available for this article.
-
Editorial for GPR84 pharmacology Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-08 Graeme Milligan
On 13th September 2022, as part of ‘Pharmacology 2022’ organised by the British Pharmacological Society, a well-attended symposium considered the topic ‘G protein-coupled receptor 84. Therapeutic opportunities in inflammation and fibrosis’. Although G protein-coupled receptor 84 (GPR84) officially remains an ‘orphan’ receptor, it is well appreciated that it can be activated by medium chain fatty acids
-
Structural bases for stoichiometry‐selective calcium potentiation of a neuronal nicotinic receptor Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-08 Simone Mazzaferro, Guipeun Kang, Kathiresan Natarajan, Ryan E. Hibbs, Steven M. Sine
Background and Purposeα4β2 nicotinic acetylcholine (nACh) receptors assemble in two stoichiometric forms, one of which is potentiated by calcium. The sites of calcium binding that underpin potentiation are not known.Experimental ApproachTo identify calcium binding sites, we applied cryo‐electron microscopy (cryo‐EM) and molecular dynamics (MD) simulations to each stoichiometric form of the α4β2 nACh
-
R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-07 Bruno Poirier, Olivier Pasquier, Xavier Chenede, Alain Corbier, Philippe Prigent, Aurélien Azam, Carine Bernard, Michel Guillotel, Florence Gillot, Laurence Riva, Veronique Briand, Raffaele Ingenito, Laurence Gauzy‐Lazo, Olivier Duclos, Christophe Philippo, Bernard Maillere, Elisabetta Bianchi, Sergio Mallart, Philip Janiak, Stephane Illiano
-
tiRNA‐Gly‐GCC‐001 in major depressive disorder: Promising diagnostic and therapeutic biomarker Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-05 Haihua Tian, Shugui Gao, Miaomiao Xu, Mei Yang, Mengyuan Shen, Jimeng Liu, Guangxue Li, Dingding Zhuang, Zhenyu Hu, Chuang Wang
Background and PurposeIn major depressive disorder (MDD), exploration of biomarkers will be helpful in diagnosing the disorder as well as in choosing a treatment and predicting the treatment response. Currently, tRNA‐derived small ribonucleic acids (tsRNAs) have been established as promising non‐invasive biomarker candidates that may enable a more reliable diagnosis or monitoring of various diseases
-
Retraction: Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non‐small cell lung cancer cells via Nrf2 inhibition Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-05
Retraction: ‘Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition’ by Xiangcui Chen, Qipeng Wu, Yueming Chen, Jiahao Zhang, Huachao Li, Zhicheng Yang, Yang Yang, Yanchao Deng, Luyong Zhang, Bing Liu, Br J Pharmacol 2019, 176: 2079–2094. The above article, published online on 1 March 2019 in Wiley Online Library
-
Retraction: A non‐erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet‐induced insulin resistance in mice Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-04
Retraction: M. Collino, E. Benetti, M. Rogazzo, F. Chiazza, R. Mastrocola, D. Nigro, J. C. Cutrin, M. Aragno, R. Fantozzi, M. A. Minetto, C. Thiemermann. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. British Journal of Pharmacology, 171: 5802–5815. https://doi.org/10.1111/bph.12888 The above article, published online on
-
Direct vagus nerve stimulation: A new tool to control allergic airway inflammation through α7 nicotinic acetylcholine receptor Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-02 Caroline Sévoz‐Couche, Wupeng Liao, Hazel Y. C. Foo, Isabelle Bonne, Thong Beng Lu, Caris Tan Qi Hui, Wendy Yen Xian Peh, Shi‐Cheng Yen, W. S. Fred Wong
Background and PurposeAsthma is characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness. The use of nicotinic agents to mimic the cholinergic anti‐inflammatory pathway (CAP) controls experimental asthma. Yet, the effects of vagus nerve stimulation (VNS)‐induced CAP on allergic inflammation remain unknown.Experimental ApproachBALB/c mice were sensitized and challenged
-
Bias translation: The final frontier? Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-03-01 Terry Kenakin
-
Regulation of depressive‐like behaviours by palmitoylation: Role of AKAP150 in the basolateral amygdala Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-28 Si‐Ying Wang, Zhi‐Xuan Xia, Shao‐Wei Yang, Wei‐Kai Chen, Yue‐Ling Zhao, Meng‐Die Li, Dan Tian, Yue Pan, Xiao‐Shan Lin, Xiao‐Qian Zhu, Zhen Huang, Jian‐Min Liu, Zhong‐Meng Lai, Wu‐Cheng Tao, Zu‐Cheng Shen
Background and PurposeProtein palmitoylation is involved in learning and memory, and in emotional disorders. Yet, the underlying mechanisms in these processes remain unclear. Herein, we describe that A‐kinase anchoring protein 150 (AKAP150) is essential and sufficient for depressive‐like behaviours in mice via a palmitoylation‐dependent mechanism.Experimental ApproachDepressive‐like behaviours in mice
-
Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-26 Rolien Bosch, Marcella Petrone, Rosalin Arends, Paolo Vicini, Eric J. G. Sijbrands, Sven Hoefman, Nelleke Snelder
-
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-20 Simone Anna Melander, Anna Thorsø Larsen, Morten Asser Karsdal, Kim Henriksen
Insulin therapies for Type 1 diabetes (T1D) have limitations, such as glucose fluctuations, hypoglycaemia, and weight gain. Only pramlintide is approved with insulin. However, its short half-life limits efficacy, requiring multiple daily injections and increasing hypoglycaemia risk. New strategies are needed to improve glycaemic control. Dual amylin and calcitonin receptor agonists are potent insulin
-
Andrographolide regulates H3 histone lactylation by interfering with p300 to alleviate aortic valve calcification Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-20 Chunli Wang, Shunshun Wang, Zijun Wang, Juanjuan Han, Nan Jiang, Linghang Qu, Kang Xu
-
Holotoxin A1 from Apostichopus japonicus inhibited oropharyngeal and intra‐abdominal candidiasis by inducing oxidative damage in Candida albicans Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-21 Min Liao, Xuekui Xia, Qingzhou Meng, Chengguang Zhu, Binyou Liao, Jiannan Wang, Lichen Gou, Xuedong Zhou, Wenpeng Yuan, Lei Cheng, Biao Ren
-
Voltage tunes mGlu5 receptor function, impacting synaptic transmission Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-19 Marin Boutonnet, Camille Carpena, Nathalie Bouquier, Yan Chastagnier, Joan Font‐Ingles, Enora Moutin, Ludovic Tricoire, Jean Chemin, Julie Perroy
-
Complement tunes glutamate release and supports synaptic impairments in an animal model of multiple sclerosis Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-19 Guendalina Olivero, Alice Taddeucci, Giulia Vallarino, Hanna Trebesova, Alessandra Roggeri, Maria Cristina Gagliani, Katia Cortese, Massimo Grilli, Anna Pittaluga
-
MicroRNA-guided drug discovery for mitigating persistent pulmonary complications in critical COVID-19 survivors: A longitudinal pilot study Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-15 María C. García-Hidalgo, Iván D. Benítez, Manel Perez-Pons, Marta Molinero, Thalía Belmonte, Carlos Rodríguez-Muñoz, María Aguilà, Sally Santisteve, Gerard Torres, Anna Moncusí-Moix, Clara Gort-Paniello, Rafael Peláez, Ignacio M. Larráyoz, Jesús Caballero, Carme Barberà, Estefania Nova-Lamperti, Antoni Torres, Jessica González, Ferran Barbé, David de Gonzalo-Calvo
-
Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-14 Yun Wang, Jiawei Wu, Yu Hong, Jiaying Zhu, Youcai Zhang, Jun Zhang, Chujie Ding, Yuan Che, Guangji Wang, Aiqin Jiang, Haiping Hao, Lijuan Cao
Panax ginseng is widely applied in the adjuvant treatment of cardiometabolic diseases in clinical practice without clear mechanisms. This study aims to clearly define the efficacy and underlying mechanism of P. ginseng and its active components in protecting against atherosclerosis.
-
Resolution pharmacology and the treatment of infectious diseases Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-14 Vivian Vasconcelos Costa, Filipe Resende, Eliza Mathias Melo, Mauro Martins Teixeira
Inflammation is elicited by the host in response to microbes, and is believed to be essential for protection against infection. However, we have previously hypothesized that excessive or misplaced inflammation may be a major contributor to tissue dysfunction and death associated with viral and bacterial infections. The resolutive phase of inflammation is a necessary condition to achieve homeostasis
-
Why classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect as agonist's efficacy Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-11 H. Ongun Onaran, Tommaso Costa
The classical theory of receptor action has been used for decades as a powerful tool to estimate molecular determinants of ligand-induced receptor activation (i.e., affinity and efficacy) from experimentally observable biological responses. However, it is also a well-recognized fact that the receptor-binding and activation mechanisms, and the parameters thereof, described in the classical theory contradict
-
The dark sides of the GPCR tree - research progress on understudied GPCRs Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-10 Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-07
No abstract is available for this article.
-
The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-07 Mikhaël Attias, Ciriaco A. Piccirillo
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune-related adverse events. The consequences of checkpoint inhibition on Foxp3+ regulatory T (Treg) cells remain unclear but could provide
-
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-06 Isabel Werle, Laura M. M. Nascimento, Aymee L. A. dos Santos, Luciane A. Soares, Rafael G. dos Santos, Jaime E. C. Hallak, Leandro J. Bertoglio
-
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-06 Tessa de Vries, Eloísa Rubio-Beltrán, Antoon van den Bogaerdt, Ruben Dammers, A. H. Jan Danser, Josefin Snellman, Jeanine Bussiere, Antoinette MaassenVanDenBrink
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for migraine treatment. Here, the effect of the monoclonal antibody erenumab on CGRP-induced vasorelaxation was investigated in human isolated blood vessels, as well as the effect of combining erenumab with the small molecule drugs, namely rimegepant, olcegepant, or sumatriptan.
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-02-02
No abstract is available for this article.
-
Correction to “Defining and unpacking the core concepts of pharmacology: A global initiative” Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-01-30
Guilding, C, White, PJ, Cunningham, M, Kelly-Laubscher, R, Koenig, J, Babey, AM, Tucker, S, Kelly, JP, Gorman, L, Aronsson, P, Hawes, M, Ngo, SNT, Mifsud, J, Werners, AH, Hinton, T, Khan, F, Aljofan, M, Angelo, T. Defining and unpacking the core concepts of pharmacology: A global initiative. Br J Pharmacol. 2024 Feb; 181(3): 375–392. doi: https://doi.org/10.1111/bph.16222 In Table 2, point 6.3, the
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-01-17
No abstract is available for this article.
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-01-11
No abstract is available for this article.
-
From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline Br. J. Pharmacol. (IF 7.3) Pub Date : 2024-01-10 Aurora Semerano, Javier Fernández-Ruiz, Marta Cortes-Canteli, María A. Moro
This article is part of a themed issue From Alzheimer's Disease to Vascular Dementia: Different Roads Leading to Cognitive Decline. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.6/issuetoc
-
Cancer microenvironment and pharmacological interventions Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-26 Mark T. S. Williams, Monica L. Guzman
LINKED ARTICLES This article is part of a themed issue on Cancer Microenvironment and Pharmacological Interventions. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.2/issuetoc
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-26
No abstract is available for this article.
-
Resveratrol, a novel inhibitor of fatty acid binding protein 5, inhibits cervical cancer metastasis by suppressing fatty acid transport into nucleus and downstream pathways Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-29 Xiao Chen, Jing Tian, Chunyuan Zhao, Yanhui Wu, Jiahuang Li, Zehan Ji, Danchen Lian, Zhibo Jia, Xingyu Chen, Zixin Zhou, Bo Zhu, Zichun Hua
-
An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-29 Janine Kutzsche, Gustavo A. Guzman, Antje Willuweit, Olaf Kletke, Esther Wollert, Ian Gering, Dagmar Jürgens, Jörg Breitkreutz, Holger Stark, Annette G. Beck-Sickinger, Nikolaj Klöcker, Patricia Hidalgo, Dieter Willbold
-
Sex-specific behavioural, metabolic, and immunohistochemical changes after repeated administration of the synthetic cannabinoid AKB48 in mice Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-27 Giorgia Corli, Elisa Roda, Micaela Tirri, Sabrine Bilel, Fabrizio De Luca, Sabina Strano-Rossi, Rosa Maria Gaudio, Fabio De-Giorgio, Liana Fattore, Carlo Alessandro Locatelli, Matteo Marti
-
Bioavailability of flumequine and diclofenac in mice exposed to a metal-drug chemical cocktail. Evaluation of the protective role of selenium. Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-27 Noemí Aranda-Merino, Antonio Marín-Garrido, Cristina Román-Hidalgo, María Ramos-Payán, Nieves Abril, Rut Fernández-Torres, Miguel Ángel Bello-López
-
Biased agonists of GPR84 and insights into biological control Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-26 Vincent B. Luscombe, Pinqi Wang, Angela J. Russell, David R. Greaves
GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reported ligands for this receptor were medium chain fatty acids with chain lengths between 9 and 12 carbons
-
Butyrate acts as a positive allosteric modulator of the 5-HT transporter to decrease availability of 5-HT in the ileum Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-21 Jieling Cai, Jamie Cheung, Samson W. M. Cheung, Karie T. C. Chin, Ricky W. K. Leung, Ronald S. T. Lam, Rakesh Sharma, Jensen H. C. Yiu, Connie W. Woo
-
Orexin-A attenuated motion sickness through modulating neural activity in hypothalamus nuclei Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-21 Leilei Pan, Shuifeng Xiao, Zichao Xu, Wenping Li, Long Zhao, Ling Zhang, Ruirui Qi, Junqin Wang, Yiling Cai
We evaluated the hypothesis that central orexin application could counteract motion sickness responses through regulating neural activity in target brain areas.
-
Protein tyrosine phosphatases as emerging targets for cancer immunotherapy Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-20 Zihan Qu, Jiajun Dong, Zhong-Yin Zhang
Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear. Protein tyrosine phosphatases (PTPs) wield a pivotal regulatory influence
-
Oat β-glucan repairs the epidermal barrier by upregulating the levels of epidermal differentiation, cell–cell junctions and lipids via Dectin-1 Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-20 Rongrong Jing, Mengli Fu, Yuhan Huang, Kaini Zhang, Jiabin Ye, Fanghua Gong, Al-bashari Jihea Ali Naji Nasser, Xiashun Xu, Jiali Xiao, Guangdong Yu, Shisheng Lin, Wengang Zhao, Nuo Xu, Xiaokun Li, Zhiming Li, Shuang Gao
Oat β-glucan could ameliorate epidermal hyperplasia and accelerate epidermal barrier repair. Dectin-1 is one of the receptors of β-glucan and many biological functions of β-glucan are mediated by Dectin-1. Dectin-1 promotes wound healing through regulating the proliferation and migration of skin cells. Thus, this study aimed to investigate the role of oat β-glucan and Dectin-1 in epidermal barrier
-
Non-canonical nitric oxide signalling and DNA methylation: Inflammation induced epigenetic alterations and potential drug targets Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-20 Christopher H. Switzer
DNA methylation controls DNA accessibility to transcription factors and other regulatory proteins, thereby affecting gene expression and hence cellular identity and function. As epigenetic modifications control the transcriptome, epigenetic dysfunction is strongly associated with pathological conditions and ageing. The development of pharmacological agents that modulate the activity of major epigenetic
-
A novel role for microtubule affinity-regulating kinases in neuropathic pain Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-19 Yao-Qin Shi, Zhi-Hong Sun, Zhe-Zhe Wang, Chun-Yu Su, Wei Zhang, Lin-Yao Yu, Yang Xu, Yong-Lin Gao, Hong-Bo Wang, Jing-Wei Tian, Chun-Mei Li
-
Integrating novel immunotherapeutic approaches in organ-preserving therapies for bladder cancer Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-13 Éva Michaud, José Joao Mansure, Wassim Kassouf
Bladder cancer (BC) is a prevalent malignancy with significant morbidity and mortality. Over the years, the landscape of bladder cancer treatment has witnessed notable advancements, particularly in the realm of immunotherapy. Immunotherapy has emerged as a promising adjunct to organ-preserving approaches, harnessing the immune system's potential to target and eliminate cancer cells. Organ preservation
-
Platelet purinergic receptors and non-thrombotic diseases Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-13 Simon C. Pitchford, Dingxin Pan
This article is part of a themed issue on Platelet purinergic receptor and non-thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc
-
Microscopy and spectroscopy approaches to study GPCR structure and function Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-12 Tomáš Fessl, Maria Majellaro, Alexey Bondar
The GPCR signalling cascade is a key pathway responsible for the signal transduction of a multitude of physical and chemical stimuli, including light, odorants, neurotransmitters and hormones. Understanding the structural and functional properties of the GPCR cascade requires direct observation of signalling processes in high spatial and temporal resolution, with minimal perturbation to endogenous
-
Extracellular ATP inhibits excitatory synaptic input on parvalbumin positive interneurons and attenuates gamma oscillations via P2X4 receptors Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-10 Florian Wildner, Tim S. Neuhäusel, Alexander Klemz, Richard Kovács, Lauriane Ulmann, Jörg R. P. Geiger, Zoltan Gerevich
P2X4 receptors (P2X4R) are ligand gated cation channels that are activated by extracellular ATP released by neurons and glia. The receptors are widely expressed in the brain and have fractional calcium currents comparable with NMDA receptors. Although P2X4Rs have been reported to modulate synaptic transmission and plasticity, their involvement in shaping neuronal network activity remains to be elucidated
-
A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-10 Liang Yang, David B. Finlay, Hayley M. Green, Xiao Zhu, Michelle Glass, Stephen Duffull
-
Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-10 Roberta Goncalves Anversa, Xavier J. Maddern, Andrew J. Lawrence, Leigh C. Walker
Neuropeptides and G protein-coupled receptors (GPCRs) have long been, and continue to be, one of the most popular target classes for drug discovery in CNS disorders, including alcohol use disorder (AUD). Yet, orphaned neuropeptide systems and receptors (oGPCR), which have no known cognate receptor or ligand, remain understudied in drug discovery and development. Orphan neuropeptides and oGPCRs are
-
Histone deacetylase-mediated silencing of PSTPIP2 expression contributes to aristolochic acid nephropathy-induced PANoptosis Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-10 Chuanting Xu, Qi Wang, Changlin Du, Lu Chen, Zhongnan Zhou, Zhenming Zhang, Na Cai, Jun Li, Cheng Huang, Taotao Ma
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-04
No abstract is available for this article.
-
Inhibition of TRPM8 function by prostacyclin receptor agonists requires coupling to Gq/11 proteins Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-03 Cosmin Trif, Alexandra-Maria Banica, Alexandra Manolache, Sorina Andreea Anghel, Debora-Elena Huţanu, Teodora Stratulat, Rodica Badea, George Oprita, Tudor Selescu, Stefana M. Petrescu, Marco Sisignano, Stefan Offermanns, Alexandru Babes, Sorin Tunaru
The TRPM8 ion channel is involved in innocuous cold sensing and has a potent anti-inflammatory action. Its activation by lower temperature or chemical agonists such as menthol and icilin induces analgesic effects, reversing hypersensitivity and reducing chronic pain. On the other hand, prostacyclin (PGI2) enhances pain and inflammation by activating the IP receptors. Due to the critical roles of TRPM8
-
Intravenous recombinant cerebellin 1 treatment restores signalling by spinal glutamate delta 1 receptors and mitigates chronic pain Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-03 Siddhesh S. Sabnis, Kishore Kumar S. Narasimhan, Poojashree B. Chettiar, Sukanya G. Gakare, Gajanan P. Shelkar, Devansh G. Asati, Shriti S. Thakur, Shashank M. Dravid
Chronic pain remains a major clinical problem that needs effective therapeutic agents. Glutamate delta 1 (GluD1) receptors and the protein cerebellin 1 (Cbln1) are down-regulated in the central amygdala (CeA) in models of inflammatory and neuropathic pain. One treatment with Cbln1, intracerebroventricularly (ICV) or in CeA, normalized GluD1 and reduced AMPA receptor expression, resulting in lasting
-
Piezo1-mediated regulation of smooth muscle cell volume in response to enhanced extracellular matrix rigidity Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-12-03 Robert T. Johnson, Reesha Solanki, Finn Wostear, Sultan Ahmed, James C. K. Taylor, Jasmine Rees, Geraad Abel, James McColl, Helle F. Jørgensen, Chris J. Morris, Stefan Bidula, Derek T. Warren
-
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-11-29 Timothée David, Aude Mallavialle, Julien Faget, Lindsay B. Alcaraz, Marion Lapierre, Pénélope Desroys du Roure, Valérie Laurent-Matha, Hanane Mansouri, Marta Jarlier, Pierre Martineau, Pascal Roger, Séverine Guiu, Thierry Chardès, Emmanuelle Liaudet-Coopman
-
Issue Information Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-11-23
No abstract is available for this article.
-
Correction to ‘Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice’ Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-11-23
Mineur, Y. S., Mose, T. N., Blakeman, S., & Picciotto, M. R. (2018). Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice. British Journal of Pharmacology, 175(11), 1903–1914. https://doi.org/10.1111/bph.13769 Upon reevaluation of the raw data of Figure 1A, the comparison between saline and MLA treatment is not statistically significant. This
-
Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase2: A new therapy target in glycocalyx shedding Br. J. Pharmacol. (IF 7.3) Pub Date : 2023-11-23 Zhi Li, Ning Wu, Jing Wang, Yang Yue, Lihua Geng, Quanbin Zhang
Diabetic vascular complication is a leading cause of disability and mortality in diabetes patients. Low molecular weight fucoidan (LMWF) is a promising drug candidate for vascular complications. Glycocalyx injury predates the occurrence of diabetes vascular complications. Protecting glycocalyx from degradation relieves diabetic vascular complications. LMWF has the potential to protect the diabetes